Gliclazide and Inflammatory marker increased - a phase IV clinical study of FDA data

Summary:

Inflammatory marker increased is reported as a side effect among people who take Gliclazide (gliclazide), especially for people who are male, 60+ old, also take Prednisolone, and have Lower respiratory tract infection.

The phase IV clinical study analyzes which people have Inflammatory marker increased when taking Gliclazide. It is created by eHealthMe based on reports of 27,903 people who have side effects when taking Gliclazide from the FDA, and is updated regularly.

What is Gliclazide?

Gliclazide has active ingredients of gliclazide. It is often used in diabetes. eHealthMe is studying from 28,131 Gliclazide users. Check the latest studies of Gliclazide.

What is Inflammatory marker increased?

Inflammatory marker increased is found to be associated with 396 drugs and 392 conditions by eHealthMe. Check the latest studies of Inflammatory marker increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

27,903 people reported to have side effects when taking Gliclazide.
Among them, 94 people (0.34%) have Inflammatory marker increased.

Could Gliclazide cause Inflammatory marker increased?

Among these 94 people:

What is the gender of people who have Inflammatory marker increased when taking Gliclazide? *

female: 23.26 %
male: 76.74 %

What is the age of people who have Inflammatory marker increased when taking Gliclazide? *

What are other drugs people take besides Gliclazide? *

What are other side effects people have besides Inflammatory marker increased? *

Sepsis (a severe blood infection that can lead to organ failure and death): 68 people, 72.34%
Fever: 68 people, 72.34%
Coughing Up Blood: 67 people, 71.28%
Lung Consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces): 67 people, 71.28%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 67 people, 71.28%
Oesophageal Carcinoma (cancer tumour of oesophagus): 67 people, 71.28%
Pleural Effusion (water on the lungs): 67 people, 71.28%
Pneumonia: 67 people, 71.28%
Rales (an abnormal respiratory sound characterized by fine crackles): 67 people, 71.28%
Lower Respiratory Tract Infection: 67 people, 71.28%

What are the existing conditions these people have? *

Lower Respiratory Tract Infection: 56 people, 59.57%
Pneumonia: 52 people, 55.32%
Gastric Ulcer (stomach ulcer): 46 people, 48.94%
Mediastinitis (inflammation of the tissues in the mid-chest): 41 people, 43.62%
Pain: 20 people, 21.28%
Pain In Extremity: 6 people, 6.38%
Polymyalgia Rheumatica (pain in many muscles): 5 people, 5.32%
Gait Disturbance: 3 people, 3.19%
Rashes (redness): 2 people, 2.13%
High Blood Pressure: 2 people, 2.13%

* Approximation only. Some reports may have incomplete information.

Do you take Gliclazide and have Inflammatory marker increased?

- Check whether Inflammatory marker increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gliclazide:

Gliclazide (28,131 reports)

Browse all side effects of Gliclazide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Inflammatory marker increased:

Inflammatory marker increased (396 drugs)

Browse all the conditions that are associated with Inflammatory marker increased:

Inflammatory marker increased (392 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gliclazide (the active ingredients of Gliclazide) and Gliclazide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.